Skip to content
Dose Brief
Menu
The shortlist

Alternatives to MEDGm

MEDGm sits at No. 185 in our ranking with a Brief Score of 66. Here are the GLP-1 providers we'd weigh against it — ranked on the same six-factor Brief Score, top down.

Prefer a straight head-to-head? CoreAge Rx vs MEDGm.

Our top alternative

No. 1 here

CoreAge Rx

CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

Coverage
US only; restrictions by state, confirmed at intake
Visit CoreAge Rx CoreAge Rx vs MEDGm →

More providers worth weighing

No. 21 · Grade B

Curex

86/100

Curex offers compounded injections and tablets, but its introductory offers, annual prices and refund promises need to be matched to the terms you accept.

Semaglutide

Confirm the selected offer

Rate sheet: $299 monthly or $2,388 annually ($199/mo equivalent).

Separate first-month offer from $49; renewal quote requires confirmation.

Full price details

Conflicting published offers: rate sheet $299/month or $2,388 annual prepayment ($199/mo equivalent); separate offer from $49 first month

Coverage
All 50 states advertised; California oral tablets only, no injections
Price trend
new to the tracker, no prior reading
Visit Read the brief →

FDA warning letter, September 2025 — issued to Curex. See the FDA's warning letter database.

No. 28 · Grade B

TeleCareSpot

85/100

TeleCareSpot publishes monthly medication programs and state exclusions, but its refund terms still contain unedited sample-policy language.

Semaglutide

From $299/mo

Monthly supply if prescribed; support and delivery where available. Confirm any separate consultation charge.

Full price details

From $299/month; monthly supply if prescribed, support and delivery where available

Coverage
Excludes Alaska, Mississippi and New Jersey; confirm selected treatment eligibility
Price trend
price stable
Visit Read the brief →
No. 49 · Grade B−

Apex MD

80/100

Apex MD includes quarterly bloodwork and provider access with its GLP-1 plans; check renewal terms and distinguish advertised tracking from proven outcomes.

Semaglutide

$299/mo compounded program

Advertised quarterly bloodwork and provider access included; confirm selected preparation.

Full price details

$299/mo compounded semaglutide program; prescribed doses, quarterly bloodwork and provider access included

Coverage
Confirm medication and clinician availability for your state
Price trend
new to the tracker, no prior reading
Visit Read the brief →
No. 149 · Grade C

MyStart Health

71/100

MyStart advertises an inclusive GLP-1 program with automatic refills, but its generic starting price does not establish separate current quotes for both medications.

Semaglutide

Confirm a named-drug quote

Generic program starts at $299/mo; a current semaglutide quote is not established. Automatic billing depends on the selected plan.

Full price details

Current named semaglutide offer and complete quote unknown; generic program starts $299/month; earlier listing: From $299/mo (all doses, compounded)

Coverage
Current medication-specific state availability requires confirmation; reviewed public pages did not establish a complete service roster
Price trend
new to the tracker, no prior reading
Visit Read the brief →

FDA warning letter, September 2025 — issued to Matthew Stern, CEO MyStart Health LLC.. See the FDA's warning letter database.

No. 173 · Grade C

Claya

69/100

Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.

Semaglutide

From $299/mo (compounded)

Coverage
Coverage not published
Price trend
new to the tracker, no prior reading
Visit Read the brief →
No. 186 · Grade C

Willow

66/100

Compounded injection and sublingual GLP-1 programs with dose-dependent pricing and an automatic-renewal cancellation deadline.

Semaglutide

$299/mo for listed standard injection tiers or sublingual tablet; higher injection tier listed at $399/mo

Coverage
36 states listed by the provider; confirm your treatment and address
Price trend
new to the tracker, no prior reading
Visit Read the brief →
No. 134 · Grade C

VirtualCare2Go

72/100

VirtualCare2Go publishes a compounded semaglutide bundle and a consultation-only route, but its shared injection tier does not guarantee tirzepatide.

Semaglutide

$279 one-month bundle

Compounded semaglutide; consultation and shipping included. The separate $99.99 consultation excludes medication.

Full price details

$279 for the listed 1-month compounded semaglutide bundle, consultation and shipping included; confirm prescribed dose

Coverage
Texas only according to the current general FAQ; confirm weight-loss program eligibility
Price trend
new to the tracker, no prior reading
Visit Read the brief →
No. 192 · Grade C

Dr. Arevitalize

68/100

Dr. Arevitalize (Dr.Arevitalize Health, Inc.) is a LegitScript-certified telehealth platform offering compounded GLP-1 weight-loss medication in both injectable and oral-capsule forms.

Semaglutide

From $319/mo (compounded)

Coverage
Coverage not published
Price trend
new to the tracker, no prior reading
Visit Read the brief →
Read our full MEDGm brief →All comparisons →

Rankings reflect the Dose Brief Score — our editorial judgment per the methodology. Pricing and coverage reflect public disclosures at last review and change often — confirm on each provider's site. Not medical advice; see our disclosure.